LakeShore Biopharma Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
LakeShore Biopharma's earnings have been declining at an average annual rate of -45.1%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 15% per year.
Wichtige Informationen
-45.1%
Wachstumsrate der Gewinne
-15.3%
EPS-Wachstumsrate
| Biotechs Wachstum der Industrie | 17.0% |
| Wachstumsrate der Einnahmen | 15.0% |
| Eigenkapitalrendite | -74.1% |
| Netto-Marge | -75.6% |
| Letzte Ertragsaktualisierung | 31 Mar 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Investors Don't See Light At End Of LakeShore Biopharma Co., Ltd's (NASDAQ:LSB) Tunnel And Push Stock Down 66%
Nov 01
LakeShore Biopharma Co., Ltd (NASDAQ:LSB) Looks Inexpensive After Falling 36% But Perhaps Not Attractive Enough
Jun 25Little Excitement Around YS Biopharma Co., Ltd.'s (NASDAQ:YS) Revenues
May 08Aufschlüsselung der Einnahmen und Ausgaben
Wie LakeShore Biopharma Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 Mar 24 | 573 | -433 | 435 | 303 |
| 31 Dec 23 | 544 | -334 | 427 | 342 |
| 30 Sep 23 | 561 | -309 | 373 | 374 |
| 30 Jun 23 | 658 | -195 | 363 | 349 |
| 31 Mar 23 | 687 | -145 | 339 | 319 |
| 31 Dec 22 | 698 | -95 | 370 | 265 |
| 30 Sep 22 | 633 | -72 | 350 | 211 |
| 30 Jun 22 | 574 | -103 | 317 | 219 |
| 31 Mar 22 | 503 | -106 | 279 | 211 |
| 31 Mar 21 | 257 | -192 | 225 | 94 |
Qualität der Erträge: LSB is currently unprofitable.
Wachsende Gewinnspanne: LSB is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: Insufficient data to determine if LSB's year-on-year earnings growth rate was positive over the past 5 years.
Beschleunigtes Wachstum: Unable to compare LSB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: LSB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: LSB has a negative Return on Equity (-74.07%), as it is currently unprofitable.